Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Dec 10, 2014; 5(5): 824-844
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.824
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.824
Positron emission tomography to assess hypoxia and perfusion in lung cancer
Eline E Verwer, Ronald Boellaard, Department of Radiology and Nuclear Medicine, VU University Medical Center, 1007 MB, Amsterdam, The Netherlands
Astrid AM van der Veldt, Department of Internal Medicine, VU University Medical Center, 1007 MB, Amsterdam, The Netherlands
Author contributions: Verwer EE and van der Veldt AAM designed and wrote the review article; Boellaard R contributed substantially to the design of the article; all authors critically revised the manuscript and approved the final version for publication.
Supported by AIRFORCE Project, No. 03O-103
Correspondence to: Astrid AM van der Veldt, MD, PhD, Department of Internal Medicine, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands. aam.vanderveldt@vumc.nl
Telephone: + 31-20-4444444 Fax: +31-20-4443090
Received: January 30, 2014
Revised: April 29, 2014
Accepted: July 15, 2014
Published online: December 10, 2014
Processing time: 315 Days and 7 Hours
Revised: April 29, 2014
Accepted: July 15, 2014
Published online: December 10, 2014
Processing time: 315 Days and 7 Hours
Core Tip
Core tip: This review provides an overview of the current applications of positron emission tomography for hypoxia and perfusion imaging in lung cancer. Available PET tracers are discussed and the benefits of combined hypoxia and perfusion PET imaging are clarified. Hypoxia imaging could aid in selecting patients for hypoxia-specific treatment strategies. To achieve this, consensus about the optimal imaging protocol and quantification method is essential. Large clinical trials are needed to confirm the value of hypoxia imaging for improving patient care.